1. A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors. Issue 2 (December 2015) Authors: Papadopoulos, Kyriakos; Tsai, Frank; Hamid, Omid; Xiao, Feng; Steele, Keith; Rebelatto, Marlon; Robbins, Paul; Karakunnel, Joyson; Lai, Dominic; Mahipal, Amit Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. Issue 1 (22nd August 2019) Authors: Naing, Aung; Infante, Jeffrey; Goel, Sanjay; Burris, Howard; Black, Chelsea; Marshall, Shannon; Achour, Ikbel; Barbee, Susannah; May, Rena; Morehouse, Chris; Pollizzi, Kristen; Song, Xuyang; Steele, Keith; Elgeioushi, Nairouz; Walcott, Farzana; Karakunnel, Joyson; LoRusso, Patricia; Weise, Amy; E... Journal: Journal for immunotherapy of cancer Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*. Issue 12 (10th October 2022) Authors: Carvelli, Julien; Meziani, Ferhat; Dellamonica, Jean; Cordier, Pierre-Yves; Allardet-Servent, Jerome; Fraisse, Megan; Velly, Lionel; Barbar, Saber Davide; Lehingue, Samuel; Guervilly, Christophe; Desgrouas, Maxime; Camou, Fabrice; Piperoglou, Christelle; Vely, Frederic; Demaria, Olivier; Karakunn... Journal: Critical care medicine Issue: Volume 50:Issue 12(2022) Page Start: 1788 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Castrate-resistant prostate cancer: the right targets and combinations. Issue 1 (January 2008) Authors: Karakunnel, Joyson; Dahut, William Journal: Therapy Issue: Volume 5:Issue 1(2008) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Issue 1 (January 2021) Authors: O'Hara, Mark H; O'Reilly, Eileen M; Varadhachary, Gauri; Wolff, Robert A; Wainberg, Zev A; Ko, Andrew H; Fisher, George; Rahma, Osama; Lyman, Jaclyn P; Cabanski, Christopher R; Mick, Rosemarie; Gherardini, Pier Federico; Kitch, Lacey J; Xu, Jingying; Samuel, Theresa; Karakunnel, Joyson; Fairchild... Journal: Lancet oncology Issue: Volume 22:Issue 1(2021) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC). (6th November 2014) Authors: Brahmer, Julie; Balmanoukian, Ani; Goldberg, Sarah; Ou, Sai-Hong; Blake-Haskins, Andrew; Karakunnel, Joyson; Stockman, Paul; Rizvi, Naiyer; Antonia, Scott Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Issue 1 (24th January 2022) Authors: Friedman, Claire F; Spencer, Christine; Cabanski, Christopher R; Panageas, Katherine S; Wells, Daniel K; Ribas, Antoni; Tawbi, Hussein; Tsai, Katy; Postow, Michael; Shoushtari, Alexander; Chapman, Paul; Karakunnel, Joyson; Bucktrout, Samantha; Gherardini, Pier; Hollmann, Travis J; Chen, Richard O... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. Issue 2 (December 2015) Authors: Kelly, Ronan; Chung, Ki; Gu, Yu; Steele, Keith; Rebelatto, Marlon; Robbins, Paul; Tavakkoli, Fatemeh; Karakunnel, Joyson; Lai, Dominic; Almhanna, Khaldoun Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. Issue 2 (December 2015) Authors: Rizvi, Naiyer; Chaft, Jamie; Balmanoukian, Ani; Goldberg, Sarah; Sanborn, Rachel; Steele, Keith; Rebelatto, Marlon; Gu, Yu; Karakunnel, Joyson; Antonia, Scott Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗